Double benefit of long-acting somatostatin analogs in a patient with coexistence of acromegaly and ulcerative colitis

---

Atıf İçin Kopyala

Yarman S., Yalin G. Y., Dogansen S. C., Canbaz B., Tanrikulu S., Akyuz F.

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, sa.5, ss.559-562, 2016 (SCI-Expanded)

• Yayın Türü: Makale / Tam Makale
• Basım Tarihi: 2016
• Doi Numarası: 10.1111/jcpt.12412
• Dergi Adı: JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
• Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
• Sayfa Sayıları: ss.559-562
• İstanbul Üniversitesi Adresli: Evet

Özet

What is known and objectiveSomatostatin analogs control GH/IGF-1 excess in acromegaly. Somatostatin receptors also mediate the complex effects of somatostatin on the gastrointestinal tract and may be defensive in inflammatory bowel diseases, such as ulcerative colitis. We present a patient who showed good response to long-acting octreotide (OCT-LAR) treatment in terms of both acromegaly and ulcerative colitis (UC). Case summaryA 58-year-old female patient with diagnosis of acromegaly and ulcerative colitis was started on long-acting somatostatin treatment as a first-line treatment for acromegaly as she refused to undergo transsphenoidal surgery. During the follow-up period, a significant amelioration was also observed in the course of ulcerative colitis, and clinical remission of both diseases was achieved uneventfully. What is new and conclusionSomatostatin appears to be a promising candidate in the treatment of inflammatory bowel diseases.